Volume 5.48 | Dec 19

Prostate Cell News 5.48 December 19, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
How Does Prostate Cancer Form?
Sirtuin enzymes have been implicated in neurodegeneration, obesity, heart disease, and cancer. Research show the loss of one of sirtuin (SIRT1) drives the formation of early prostate cancer in mouse models of the disease. [Press release from Thomas Jefferson University (EurekAlert!) discussing online prepublication in The American Journal of Pathology] Press Release | Full Article
Request Sample: ReLeSR™, Easy Passaging Through Selective Detachment of hPSCs
PUBLICATIONS (Ranked by impact factor of the journal)

PIM Kinase Inhibitor AZD1208 for Treatment of MYC-Driven Prostate Cancer
Scientists examined the effects of a novel oral PIM inhibitor, AZD1208, on prostate tumorigenesis and recurrence. AZD1208 inhibited tumorigenesis in tissue recombinants, Myc-CaP, and human prostate cancer xenograft models. PIM inhibition decreased c-MYC/Pim1 graft growth, decreased cellular proliferation, and increased apoptosis. [J Natl Cancer Inst] Abstract

The Role of TXNDC5 in Castration-Resistant Prostate Cancer – Involvement of Androgen Receptor Signaling Pathway
Scientists demonstrate that thioredoxin domain-containing protein 5 (TXNDC5) is up-regulated following long-term androgen-deprivation treatment and is highly overexpressed in castration-resistant prostate cancer tumors compared with hormone-naive prostate cancer (PCa) cases. Functionally, in vitro and in vivo studies demonstrated that TXNDC5 overexpression promotes the growth of both androgen-dependent and castration-resistant PCa xenografts. [Oncogene] Abstract

Loss of JUNB/AP-1 Promotes Invasive Prostate Cancer
Researchers show that the transcription factor JUNB/AP-1 limits prostate cancer progression. JUNB expression is increased in low-grade prostate cancer compared with normal human prostate, but downregulated in high-grade samples and further decreased in all metastatic samples. [Cell Death Differ] Abstract

PRK1/PKN1 Controls Migration and Metastasis of Androgen-Independent Prostate Cancer Cells
Scientists show that metastatic behavior of androgen-independent prostate tumor cells requires the protein-kinase-C-related kinase (PRK1/PKN1) in vitro and in vivo. PRK1 regulates cell migration and gene expression through its kinase activity, but does not affect cell proliferation. [Oncotarget] Full Article

miR-223-3p Targeting SEPT6 Promotes the Biological Behavior of Prostate Cancer
Investigators found microRNA (miR)-223-3p were up-regulated in prostate cancer tissues and then studied functional roles of miR-223-3p in prostate cancer using DU145, PC3 and LNCaP cell lines. [Sci Rep]
Full Article

Inhibition of Polo-Like Kinase 1 (Plk1) Enhances the Anti-Neoplastic Activity of Metformin in Prostate Cancer
Researchers show that BI2536, a specific Plk1 inhibitor, acts synergistically with metformin in inhibiting prostate cancer cell proliferation. They also provide evidence that Plk1 inhibition renders prostate cancer cells carrying wild type p53 to be much more sensitive to low dose metformin treatment. [J Biol Chem]
Abstract | Full Article

Diosmin Induces Genotoxicity and Apoptosis in DU145 Prostate Cancer Cell Line
Cyto- and genotoxicity of three selected flavonoid glycosides in DU145 prostate cancer cell line were investigated. Flavonoid glycosides decreased cancer cell number and proliferative activity in a different manner. [Toxicol In Vitro] Abstract

Targeting Prostate Cancer Cell Metabolism: Impact of Hexokinase and CPT-1 Enzymes
Researchers evaluated the involvement of hexokinase and CPT-1 in the cell growth and proliferation of human prostate cancer cell lines, PC3, and LNCaP-FGC-10. [Tumor Biol] Abstract

MicroRNA-218 Inhibits Prostate Cancer Cell Growth and Promotes Apoptosis by Repressing TPD52 Expression
Scientists explored the regulative role of miR-218, a tumor suppressing miRNA on tumor protein D52 (TPD52) expression and prostate cancer cell proliferation. They found the expression of miR-218 was significantly lower in prostate cancer specimens. [Biochem Biophys Res Commun] Abstract


Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients with Prostate Cancer
Scientists report the long-term outcome of a large active surveillance protocol in men with favorable-risk prostate cancer. Main outcome measures were overall and disease-specific survival, rate of treatment, and prostate-specific antigen failure rate in the treated patients. [J Clin Oncol] Abstract

Neutrophil to Lymphocyte Ratio as a Prognostic Biomarker for Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Chemotherapy: Data from Two Randomized Phase III Trials
Researchers investigated associations of the derived neutrophil to lymphocyte ratio and duration of initial androgen deprivation therapy with survival of men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy. [Ann Oncol] Abstract

[Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now
Targeting Heat Shock Proteins in Metastatic Castration-Resistant Prostate Cancer
The integral role of heat shock proteins (HSPs) in androgen receptor (AR) function speaks to their potential utility as therapeutic targets in castration-resistant prostate cancer (CRPC), a disease state characterized by persistent activation of the androgen-AR axis. Inhibition of HSPs has the additional benefit of potentially modulating signalling and transcriptional networks that are associated with HSP client proteins in CRPC cells. [Nat Rev Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
BC Cancer Agency Researchers Co-Lead $60 Million National Initiative for Innovative Cancer Treatments
BC Cancer Agency researchers will play a key role in the first Network of Centers of Excellence devoted to cancer research, announced with a $25 million commitment from the Government of Canada and an additional $35 million from partners across the country. [BC Cancer Agency] Press Release

Sophiris Bio Reports Administrative Interim Analysis for the “PLUS-1” Phase III Trial of PRX302 for Benign Prostatic Hyperplasia
Sophiris Bio Inc. announced findings from an administrative interim analysis of efficacy in its ongoing Phase III “PLUS-1” trial of PRX302 as a treatment for lower urinary tract symptoms of benign prostatic hyperplasia. [Sophiris Bio Inc.] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 3rd Global Congress on Prostate Cancer
February 4-6, 2015
Rome, Italy

NEW 4th International Conference on Immunochemotherapy
April 16-17, 2015
Philadelphia, United States

Visit our events page to see a complete list of events in the prostate cell community.
NEW PhD Student Position – Prostate Cancer Translational Research (Innsbruck Medical University)

Postdoctoral Research Associate Positions – Cancer Biology (Hollings Cancer Center)

Postdoctoral Positions – Prostate Cancer Epigenetics and Genomics (UT Southwestern Medical Center at Dallas)

Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK Manchester Institute)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Postdoctoral Position – Prostate Cancer and Prostatic Diseases (Louisiana State University)

Postdoctoral Associate – Biomarkers Associated with Prostate Cancer (Duke Molecular Physiology Institute)

Postdoctoral Fellow – Metabolomics and Prostate Cancer (University of Maryland)

Research Technologist – Media Development (STEMCELL Technologies Inc.)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us